Omaron, tablets 30 pcs

Combined medicine with pronounced antihypoxic, nootropic and vasodilator effect.

Piracetam activates metabolic processes in the brain by enhancing energy and protein metabolism, accelerating glucose utilization by cells and increasing their resistance to hypoxia;

improves inter-neuronal transmission in the central nervous system, improves regional blood flow in the ischemic area.

Cinnarizine is a selective blocker of “slow” calcium channels, reduces the entry of calcium ions into cells and reduces its content in the plasma membrane depot, reduces the tone of arteriolar smooth muscle,

reduces their response to biogenic vasoconstrictors (adrenaline, noradrenaline, dopamine, angiotensin II, vasopressin, serotonin).

It has a vasodilator effect (especially on brain vessels, increasing the antihypoxic effect of piracetam), without a significant effect on blood pressure.

It has moderate antihistamine activity, decreases the excitability of the vestibular system, reduces the tone of the sympathetic nervous system.

Increases elasticity of erythrocyte membranes, their ability to deform, reduces blood viscosity.

Absorption. After oral administration piracetam and cinnarizine are quickly and almost completely absorbed in the gastrointestinal tract. Bioavailability of piracetam is about 100%.

Maximum concentration (Cmax) of piracetam is reached 0.5-1 hour after intake. The maximum concentration of cinnarizine in plasma is reached after 1-3 hours. Bioavailability of cinnarizine increases in acidic environment.

Distribution. Piracetam does not bind with blood plasma proteins. The volume of distribution is about 0.6 l/kg.

Passes through the blood-brain and placental barriers, to all organs and tissues, as well as through filter membranes used in hemodialysis.

In animal studies it was found that piracetam selectively accumulates in cortical tissues, mainly in the frontal, parietal and occipital lobes, cerebellum and basal ganglia.

Cinnarizine. Binding with plasma proteins is 91%. In 1-4 hours after oral administration it is found in liver, kidneys, heart, lungs, spleen and brain.

Metabolism. Piracetam is virtually unmetabolized in the body.

Cinnarizine is actively and completely metabolized by dealkylation; the metabolic process begins 30 minutes after oral administration.

Excretion. Piracetam. More than 95% of the oral dose is excreted unchanged by the kidneys by renal filtration within 30 hours.

Renal clearance of piracetam in healthy volunteers is 86 ml/minute. Half-life (T1/2) is 4-5 hours from blood plasma and 8.5 hours from cerebrospinal fluid.

In patients with renal insufficiency T1/2 is prolonged. In patients with hepatic insufficiency pharmacokinetics of piracetam does not change.

Cinnarizine is excreted from the body as metabolites (1/3 – by kidneys, 2/3 – through intestine), T1/2 – about 4 hours.

Indications

Asthenia, Stroke sequelae, Dizziness, Prevention of heart attacks and strokes, Concussion and other craniocerebral injuries, Circulatory disorders, Motion sickness, Tinnitus, Attention and memory disorders, Meniere’s disease, Atherosclerosis

• Applications for use of Omaron: cerebral circulatory insufficiency (atherosclerosis of brain vessels, recovery period of ischemic and hemorrhagic strokes, craniocerebral injuries, encephalopathies of various genesis), intoxications
• Other diseases of the central nervous system, accompanied by decreased intellectual and mental functions (memory, attention, mood), psycho-organic syndrome with predominant signs of asthenia and adynamy, asthenic syndrome
• labyrinthopathy, Meniere’s syndrome
• reduction of intellectual development in children, prevention of migraine and kinetosis.With

.

Active ingredient

Piracetam, Cinnarizin

Composition

Active ingredients:

Piracetam 400 mg;

Cinnarizin 25 mg;

Excipients:

Lactose monohydrate 23.5 mg;

Magnesium hydroxycarbonate pentahydrate 46.8 mg;

Povidone (collidon 30) 3.9 mg;
<
Colloidal silicon dioxide (Aerosil A-380) 5.2 mg,

Calcium stearate monohydrate 5.2 mg;

Crospovidone (collidon SL-M) 10.4 mg.

How to take, the dosage

Orally, during or after meals.

Adults: 1-2 tablets 3 times a day for 1-3 months, depending on the severity of the disease. It is possible to have repeated courses of treatment 2-3 times a year.

Children over 5 years: 1-2 tablets 1-2 times a day. Not to be used more than 3 months.

For prevention of motion sickness: in adults – 1 tablet, in children over 5 years old – 1/2 tablet 30 minutes before the trip, with repeated administration (if necessary) every 6-8 hours.

Patients with impaired renal function: in chronic renal failure (creatinine clearance 20-80 ml/min) – 1 tablet 2 times a day.

Interaction

When concomitant use may increase the sedative effect of agents that depress the central nervous system, as well as ethanol, nootropic and antihypertensive agents.

Vasodilators increase the effect of the drug.

It improves tolerability of antipsychotic drugs and tricyclic antidepressants.

When used concomitantly, piracetam increases the central effects of thyroid hormones (tremor, restlessness, irritability, sleep disturbances are possible); it may increase the effect of oral anticoagulants.

Special Instructions

In long-term use, monitoring of liver and renal function is recommended (especially in patients with chronic renal failure).

During treatment, patients with arterial hypotension may have a more significant decrease in BP.

The use of alcohol during treatment is not recommended.

The results of doping tests and allergic skin tests may be distorted; the drug should be discontinued 4 days before the study.

Impact on driving and operating machinery

When using the drug, caution should be exercised while driving motor vehicles and engaging in other potentially dangerous activities requiring increased concentration and quick psychomotor reactions.

.

Contraindications

Hypersensitivity to the main and/or auxiliary components of the drug; severe hepatic insufficiency; severe renal insufficiency (creatinine clearance less than 20 ml/min); hemorrhagic stroke; Parkinsonism (including Parkinson’s disease); psychomotor agitation; Huntington’s disease; pregnancy;

lactation; children under 5 years old; lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome (drug contains lactose).

With caution

Hepatic and/or renal diseases, chronic renal insufficiency (creatinine clearance 20-80 ml/min);

elevated intraocular pressure; porphyria; Haemostasis disorder; extensive surgical interventions;

severe bleeding; hyperthyroidism; epilepsy; pronounced atherosclerosis of cerebral vessels; susceptibility to neurotic reactions.

Side effects

Central and peripheral nervous system disorders: motor disinhibition, irritability, somnolence, depression, asthenia, headache.

In single cases dizziness, ataxia, worsening of epilepsy, extrapyramidal disorders, tremor, unsteadiness, decreased ability to concentrate, insomnia, agitation, anxiety, hallucinations, increased sexuality have been reported.

Cardiovascular system: decreased or increased BP.

Digestive system disorders: dyspeptic phenomena, feeling of dry mouth; in single cases – nausea, vomiting, diarrhea, abdominal pain, cholestatic jaundice.

Skin disorders: dermatitis, itching, skin rash in single cases.

Metabolism: weight gain.

Allergic reactions: angioedema.

Others: increased sweating; in single cases – lupus-like syndrome, lichen planus.

.

Overdose

Symptoms of overdose mainly due to the m-cholin-blocking activity of cinnarizine include: impaired consciousness, vomiting, extrapyramidal symptoms, decreased blood pressure. Bloody diarrhea and abdominal pain were observed after oral administration of piracetam at a dose of 75 g.

Treatment: there is no specific antidote. In case of overdose gastric lavage and administration of activated charcoal, symptomatic and supportive therapy are necessary. The effectiveness of hemodialysis for piracetam is 50-60%.

.

Pregnancy use

The drug is contraindicated in pregnancy and lactation.

.

Similarities

Fezam, Combitropil